Stocks and Investing Stocks and Investing
Thu, April 11, 2024

Liisa Bayko Upgraded (VRTX) to Buy and Held Target at $438 on, Apr 11th, 2024


Published on 2024-10-28 10:16:55 - WOPRAI, Liisa Bayko
  Print publication without navigation


Liisa Bayko of Evercore ISI Group, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Buy and Held Target at $438 on, Apr 11th, 2024.

Liisa has made no other calls on VRTX in the last 4 months.



There are 11 other peers that have a rating on VRTX. Out of the 11 peers that are also analyzing VRTX, 3 agree with Liisa's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $420 on, Tuesday, February 6th, 2024
  • William Pickering of "Bernstein" Downgraded from Buy to Hold on, Friday, February 2nd, 2024
  • Naz Rahman of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, January 31st, 2024


These are the ratings of the 8 analyists that currently disagree with Liisa


  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $440 on, Tuesday, February 20th, 2024
  • Andy Chen of "Wolfe Research" Initiated at Buy on, Thursday, February 15th, 2024
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $472 on, Tuesday, February 6th, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $450 on, Tuesday, February 6th, 2024
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $540 on, Tuesday, February 6th, 2024
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $508 on, Wednesday, January 31st, 2024
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $559 on, Wednesday, January 31st, 2024
  • Whitney Ijem of "Canaccord Genuity" Downgraded from Hold to Strong Sell and Increased Target to $379 on, Wednesday, January 24th, 2024
Contributing Sources